Rashid Lui, Associate Consultant at Hospital Authority and Honorary Clinical Assistant Professor at CUHK Medicine, shared a post on LinkedIn:
“The latest ESMO – European Society for Medical Oncology guidelines for metastatic colorectal cancer is now out in Annals of Oncology!
Molecular testing on the primary tumour or metastatic sites is recommended in ALL patients at the time of mCRC diagnosis.
Recommended testing include extended RAS, BRAF-V600E, MMR/MSI status and HER2 overexpression and/or amplification.
Increasingly important role of ctDNA.
The importance of multidisciplinary teams MDT.
Locoregional therapies for limited metastatic disease.
Hierarchal management approach for systemic therapy guided by biomarkers.
More comprehensive management algorithm for later lines of therapy.”
Title: Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Authors: C. Cremolini, M. Chalabi, E. Elez, M. Fassan, M. Gelli, D. Goéré, D.P. Modest, C. Montagut, P. Osterlund, J. Ricke, J. Seligmann, J. Taieb, T. Yoshino, L. Wyrwicz, M. Ducreux
Read The Full Article
Other articles about ESMO on OncoDaily.